ioGenetics has developed an integrated pipeline that includes the platform technologies to efficiently design and produce a diverse array of recombinant proteins. This has enabled it to develop new products including vaccines, and therapeutics. The company has built an extensive intellectual property portfolio of both products and technologies. The primary focus has been on design and development of proprietary antimicrobial proteins. These include anticryptosporidial, antistaphylococcal products, and antiviral products. Utilizing its proprietary RPex retrovector platform in mammalian cells, ioGenetics has created many novel antibodies and antibody fusion products.
To learn about licensing opportunities click here to contact ioGenetics.